肺癌治療薬の世界市場2019-2023

Technavioが出版した調査資料(IRTNTR31000)・商品コード:IRTNTR31000
・発行会社(調査会社):Technavio
・発行日:2019年3月6日
・ページ数:121
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
・産業分野:Health Care
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥321,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、肺癌治療薬の世界市場について調査・分析し、市場概要、市場環境、肺癌治療薬市場規模、種類別(NSCLC、SCLC)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・肺癌治療薬の世界市場概要
・肺癌治療薬の世界市場環境
・肺癌治療薬の世界市場動向
・肺癌治療薬の世界市場規模
・肺癌治療薬の世界市場:業界構造分析
・肺癌治療薬の世界市場:種類別(NSCLC、SCLC)
・肺癌治療薬の世界市場:地域別市場規模・分析
・肺癌治療薬の北米市場規模・予測
・肺癌治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・肺癌治療薬のアジア太平洋市場規模・予測
・肺癌治療薬の主要国分析
・肺癌治療薬の世界市場:意思決定フレームワーク
・肺癌治療薬の世界市場:成長要因、課題
・肺癌治療薬の世界市場:競争環境
・肺癌治療薬の世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

About this market
The global lung cancer therapeutics market has witnessed significant growth in recent years, primarily due to the increasing approval of immunomodulators. Vendors are conducting research on various types of cancer using these therapies. The market currently has only a limited number of checkpoint inhibitors, but these drugs contribute significantly to the global lung cancer therapeutics market. The high proven efficacy and the increasing popularity of these drugs are expected to contribute significantly to the growth of the global lung cancer therapeutics market during the forecast period. Technavio’s analysts have predicted that the lung cancer therapeutics market will register a CAGR of about 13% by 2023.
Market Overview
Strong prevalence of lung cancer
Lung cancer is one of the most common cancer types. It is also the most common cause of cancer-related deaths globally. The new cases of cancer, especially lung cancer, have increased significantly in recent years, owing to factors such as the increasing geriatric population and lifestyle changes.
Adherence to available alternatives
The increasing advances in the diagnostic methods for lung cancer. These advances are leading to the early detection of lung cancer and are resulting in the increasing use of surgeries and radiation therapy for the treatment of the disease. This is expected to reduce the scope of therapeutics for the treatment of lung cancer, thus reducing patient adherence to lung cancer therapeutics. Thus, the increasing patient adherence to the available alternatives is expected to limit the growth of the global lung cancer therapeutics market during the forecast period.
For the detailed list of factors that will drive and challenge the growth of the lung cancer therapeutics market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be moderately concentrated and with the presence of limited vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: PIPELINE
PART 07: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• NSCLC – Market size and forecast 2018-2023
• SCLC – Market size and forecast 2018-2023
• Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
PART 15: APPENDIX
• Research methodology
• List of abbreviations
PART 16: EXPLORE TECHNAVIO


Exhibit 01: Global oncology therapeutics market
Exhibit 02: Segments of global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition – Five forces 2018
Exhibit 17: Global lung cancer therapeutics market pipeline: Overview
Exhibit 18: Global lung cancer therapeutics market pipeline: Overview
Exhibit 19: Type – Market share 2018-2023 (%)
Exhibit 20: Comparison by type
Exhibit 21: NSCLC – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: NSCLC – Year-over-year growth 2019-2023 (%)
Exhibit 23: SCLC – Market size and forecast 2018-2023 ($ millions)
Exhibit 24: SCLC – Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by type
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America – Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in North America
Exhibit 32: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in Europe
Exhibit 35: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Asia
Exhibit 38: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in ROW
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: New cases and mortality rates of lung cancer in 2008
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Bristol-Myers Squibb Company – Vendor overview
Exhibit 51: Bristol-Myers Squibb Company – Business segments
Exhibit 52: Bristol-Myers Squibb Company – Organizational developments
Exhibit 53: Bristol-Myers Squibb Company – Geographic focus
Exhibit 54: Bristol-Myers Squibb Company – Key offerings
Exhibit 55: Bristol-Myers Squibb Company – Key customers
Exhibit 56: F. Hoffmann-La Roche Ltd – Vendor overview
Exhibit 57: F. Hoffmann-La Roche Ltd – Business segments
Exhibit 58: F. Hoffmann-La Roche Ltd – Organizational developments
Exhibit 59: F. Hoffmann-La Roche Ltd – Geographic focus
Exhibit 60: F. Hoffmann-La Roche Ltd – Segment focus
Exhibit 61: F. Hoffmann-La Roche Ltd – Key offerings
Exhibit 62: F. Hoffmann-La Roche Ltd – Key customers
Exhibit 63: Merck & Co., Inc. – Vendor overview
Exhibit 64: Merck & Co., Inc. – Business segments
Exhibit 65: Merck & Co., Inc. – Organizational developments
Exhibit 66: Merck & Co., Inc. – Geographic focus
Exhibit 67: Merck & Co., Inc. – Segment focus
Exhibit 68: Merck & Co., Inc. – Key offerings
Exhibit 69: Merck & Co., Inc. – Key customers
Exhibit 70: Novartis AG – Vendor overview
Exhibit 71: Novartis AG – Business segments
Exhibit 72: Novartis AG – Organizational developments
Exhibit 73: Novartis AG – Geographic focus
Exhibit 74: Novartis AG – Segment focus
Exhibit 75: Novartis AG – Key offerings
Exhibit 76: Novartis AG – Key customers
Exhibit 77: Pfizer Inc. – Vendor overview
Exhibit 78: Pfizer Inc. – Business segments
Exhibit 79: Pfizer Inc. – Organizational developments
Exhibit 80: Pfizer Inc. – Geographic focus
Exhibit 81: Pfizer Inc. – Segment focus
Exhibit 82: Pfizer Inc. – Key offerings
Exhibit 83: Pfizer Inc. – Key customers
Exhibit 84: Validation techniques employed for market sizing



【掲載企業】

Bristol-Myers Squibb Company、F. Hoffmann-La Roche Ltd、Merck & Co., Inc.、Novartis AG、Pfizer Inc.

★調査レポート[肺癌治療薬の世界市場2019-2023] (コード:IRTNTR31000)販売に関する免責事項を必ずご確認ください。
★調査レポート[肺癌治療薬の世界市場2019-2023]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆